

Yin-Cheong Wong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6500063/publications.pdf>

Version: 2024-02-01

26
papers

858
citations

516710

16
h-index

552781

26
g-index

27
all docs

27
docs citations

27
times ranked

1306
citing authors

#	ARTICLE	IF	CITATIONS
1	Kinetics for Drug Discovery: an industry-driven effort to target drug residence time. <i>Drug Discovery Today</i> , 2017, 22, 896-911.	6.4	165
2	Development, characterization and application of in situ gel systems for intranasal delivery of tacrine. <i>International Journal of Pharmaceutics</i> , 2014, 468, 272-282.	5.2	94
3	Predicting Drug Concentration–Time Profiles in Multiple CNS Compartments Using a Comprehensive Physiologically–Based Pharmacokinetic Model. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 765-777.	2.5	61
4	A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations. <i>Pharmaceutical Research</i> , 2017, 34, 333-351.	3.5	59
5	Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 112, 168-179.	4.0	59
6	Development of a SPE-LC/MS/MS method for simultaneous quantification of baicalin, wogonin, oroxylin A and their glucuronides baicalin, wogonoside and oroxyloside in rats and its application to brain uptake and plasma pharmacokinetic studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 97, 9-23.	2.8	57
7	Intranasal Delivery–Modification of Drug Metabolism and Brain Disposition. <i>Pharmaceutical Research</i> , 2010, 27, 1208-1223.	3.5	42
8	Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1207-1218.	5.0	35
9	Structure–activity relationships of the glucuronidation of flavonoids by human glucuronosyltransferases. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 1399-1419.	3.3	33
10	Herb–drug interactions between <i>Scutellariae Radix</i> and mefenamic acid: Simultaneous investigation of pharmacokinetics, anti-inflammatory effect and gastric damage in rats. <i>Journal of Ethnopharmacology</i> , 2015, 170, 106-116.	4.1	32
11	Mechanistic models enable the rational use of <i>in vitro</i> drug-target binding kinetics for better drug effects in patients. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 45-63.	5.0	27
12	Investigation of the disposition of loxapine, amoxapine and their hydroxylated metabolites in different brain regions, CSF and plasma of rat by LC–MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 58, 83-93.	2.8	25
13	Brain Uptake of Bioactive Flavones in <i>Scutellariae Radix</i> and Its Relationship to Anxiolytic Effect in Mice. <i>Molecular Pharmaceutics</i> , 2017, 14, 2908-2916.	4.6	25
14	Intestinal first-pass glucuronidation activities of selected dihydroxyflavones. <i>International Journal of Pharmaceutics</i> , 2009, 366, 14-20.	5.2	24
15	Brain Disposition and Catalepsy After Intranasal Delivery of Loxapine: Role of Metabolism in PK/PD of Intranasal CNS Drugs. <i>Pharmaceutical Research</i> , 2013, 30, 2368-2384.	3.5	22
16	Intranasal delivery of a novel acetylcholinesterase inhibitor HLS-3 for treatment of Alzheimer's disease. <i>Life Sciences</i> , 2018, 207, 428-435.	4.3	18
17	Regioselective biotransformation of CNS drugs and its clinical impact on adverse drug reactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 833-854.	3.3	12
18	Alterations in the CNS effects of anti-epileptic drugs by Chinese herbal medicines. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 249-267.	3.3	12

#	ARTICLE	IF	CITATIONS
19	Utility of Animal Models to Understand Human Alzheimer's Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3158.	4.1	12
20	Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling. <i>AAPS Journal</i> , 2017, 19, 274-285.	4.4	10
21	Pharmacokinetic Comparison Between the Long-Term Anesthetized, Short-Term Anesthetized and Conscious Rat Models in Nasal Drug Delivery. <i>Pharmaceutical Research</i> , 2014, 31, 2107-2123.	3.5	9
22	Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 731-747.	2.0	9
23	Fingerprints of CNS drug effects: a plasma neuroendocrine reflection of D ₂ receptor activation using multi-biomarker pharmacokinetic/pharmacodynamic modelling. <i>British Journal of Pharmacology</i> , 2018, 175, 3832-3843.	5.4	7
24	Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in non-anesthetized rat. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 111, 514-525.	4.0	6
25	Identification and disposition of novel mono-hydroxyl mefenamic acid and their potentially toxic O-acetylglucuronides <i>in vivo</i> . <i>Biopharmaceutics and Drug Disposition</i> , 2015, 36, 529-551.	1.9	2
26	Comment on Uridine Diphosphate Glucuronosyltransferase Isoform-Dependent Regiospecificity of Glucuronidation of Flavonoids: Applicability of UV Spectrum Shifts in Identification of Glucuronidation Position in Flavones and Flavonols. <i>Journal of Agricultural and Food Chemistry</i> , 2012, 60, 4416-4419.	5.2	1